Zymeworks Beats Q3 2026 Estimates as Revenue Rises 829% to $256.5M

Zymeworks (ZYME) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $256.5 million, up 829% from a year earlier, above the $227.4 million estimate, and adjusted EPS was $2.28 above the $2.27 estimate.

Shares were unchanged in after-hours trading as of 4:04 p.m. ET, to $30.81 from a $30.81 close.

Q3 2026 scorecard

By our calculation, revenue was $29.1 million above the estimate and adjusted EPS was $0.01 above it. The QoQ column compares with the previous quarter's revenue of $4.6 million and adjusted EPS of -$0.62. The YoY column compares with $27.6 million and -$0.26 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 4 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 6 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $27.6 million, $2.5 million, $2.4 million, $4.6 million and $256.5 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of $0.05 and revenue of $65.6 million next quarter, based on 6 analysts.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 829% increase to $256.5 million.
• Estimate record. Whether Zymeworks extends a record of beating EPS estimates in 4 of its last 8 reports.
• Related coverage. See our reports on GeneDx, WEBTOON Entertainment, Take-Two Interactive Software and Life360.

Sources: Results are from Zymeworks's Nov. 9, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Zymeworks's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.